Efficacy of a "Rescue" Ciprofloxacin-Based Regimen for Eradication of Helicobacter pylori Infection after Treatment Failures
- PMID: 22666234
- PMCID: PMC3359787
- DOI: 10.1155/2012/484591
Efficacy of a "Rescue" Ciprofloxacin-Based Regimen for Eradication of Helicobacter pylori Infection after Treatment Failures
Abstract
The aim of our study was to evaluate the efficacy and tolerability of a ciprofloxacin-based regimen for H. pylori eradication failures as an alternative to bismuth based quadruple therapy. Methods.
Design: prospective single-center study. Patients in whom a first eradication trial with omeprazole/esomeprazole, clarithromycin plus amoxicillin or tinidazole/metronidazole had failed were included. H. pylori status: established by histology, rapide urease test and polymerase chain reaction.
Intervention: esomeprazole 20 mg, ciprofloxacin 500 mg, and metronidazole 500 mg, administered together before breakfast and dinner for 10 days. Susceptibility testing was performed by the Epsilometer test. Ciprofloxacin resistance was defined as a MIC of ≥1 μg/mL. Eradication was established by a negative 13C-UBT and 4-6 weeks post-therapy. Efficacy and side effects were determined. Results. 34 patients were enrolled, 32 completed the study. Compliance was excellent (100%). Side effects were mild. Ciprofloxacin-based therapy cured 65% (22/34) of patients by intention to treat and 69% (22/32) per protocol analysis. The prevalence of ciprofloxacin resistance was 8%. Conclusions. The effectiveness of ciprofloxacin-based therapy was greatly reduced despite the high prevalence of ciprofloxacin sensitive H. pylori strains. Bismuth based quadruple therapy still remain the best choice as a "rescue" regimen in our region.
Similar articles
-
'Rescue' therapy with rifabutin after multiple Helicobacter pylori treatment failures.Helicobacter. 2003 Apr;8(2):90-4. doi: 10.1046/j.1523-5378.2003.00128.x. Helicobacter. 2003. PMID: 12662375 Clinical Trial.
-
Efficacy and Tolerability of Two Quadruple Regimens: Bismuth, Omeprazole, Metronidazole with Amoxicillin or Tetracycline as First-Line Treatment for Eradication of Helicobacter Pylori in Patients with Duodenal Ulcer: A Randomized Clinical Trial.PLoS One. 2018 Jun 11;13(6):e0197096. doi: 10.1371/journal.pone.0197096. eCollection 2018. PLoS One. 2018. PMID: 29889843 Free PMC article. Clinical Trial.
-
[Helicobacter pylori eradication in patients with peptic ulcer after two treatment failures: a prospective culture-guided study].Gastroenterol Hepatol. 2002 Aug-Sep;25(7):438-42. doi: 10.1016/s0210-5705(02)70283-5. Gastroenterol Hepatol. 2002. PMID: 12139836 Clinical Trial. Spanish.
-
Seven-Day Bismuth-based Quadruple Therapy as an Initial Treatment for Helicobacter pylori Infection in a High Metronidazole Resistant Area.Asian Pac J Cancer Prev. 2015;16(14):6089-92. doi: 10.7314/apjcp.2015.16.14.6089. Asian Pac J Cancer Prev. 2015. PMID: 26320500
-
Optimum duration of regimens for Helicobacter pylori eradication.Cochrane Database Syst Rev. 2013 Dec 11;(12):CD008337. doi: 10.1002/14651858.CD008337.pub2. Cochrane Database Syst Rev. 2013. PMID: 24338763 Review.
Cited by
-
The resistance mechanisms of bacteria against ciprofloxacin and new approaches for enhancing the efficacy of this antibiotic.Front Public Health. 2022 Dec 21;10:1025633. doi: 10.3389/fpubh.2022.1025633. eCollection 2022. Front Public Health. 2022. PMID: 36620240 Free PMC article. Review.
-
The impact of oral ciprofloxacin on the structure and functions of rat gastric mucosa.Saudi J Biol Sci. 2022 Apr;29(4):2187-2198. doi: 10.1016/j.sjbs.2021.11.042. Epub 2021 Nov 24. Saudi J Biol Sci. 2022. PMID: 35531231 Free PMC article.
-
Culture-based antibiotic susceptibility testing for Helicobacter pylori infection: a systematic review.Ann Gastroenterol. 2022 Mar-Apr;35(2):127-134. doi: 10.20524/aog.2022.0689. Epub 2022 Feb 14. Ann Gastroenterol. 2022. PMID: 35479595 Free PMC article.
-
Two-week bismuth-containing quadruple therapy and concomitant therapy are effective first-line treatments for Helicobacter pylori eradication: A prospective open-label randomized trial.World J Gastroenterol. 2019 Dec 14;25(46):6790-6798. doi: 10.3748/wjg.v25.i46.6790. World J Gastroenterol. 2019. PMID: 31857780 Free PMC article. Clinical Trial.
-
Reply to letter to the editor: "The dosage of rifabutin in H. pylori eradication regimen should be appropriately determined in each area of the world".United European Gastroenterol J. 2016 Jun;4(3):476-7. doi: 10.1177/2050640616631477. Epub 2016 May 27. United European Gastroenterol J. 2016. PMID: 27403316 Free PMC article. No abstract available.
References
-
- Realdi G, Dore MP, Piana A, et al. Pretreatment antibiotic resistance in Helicobacter pylori infection: results of three randomized controlled studies. Helicobacter. 1999;4(2):106–112. - PubMed
-
- Graham DY. Therapy of Helicobacter pylori: current status and issues. Gastroenterology. 2000;118(2, supplement 1):S2–S8. - PubMed
-
- Dore MP, Graham DY, Mele R, et al. Colloidal bismuth subcitrate-based twice-a-day quadruple therapy as primary or salvage therapy for Helicobacter pylori infection. The American Journal of Gastroenterology. 2002;97(4):857–860. - PubMed
-
- Dore MP, Marras L, Maragkoudakis E, et al. Salvage therapy after two or more prior Helicobacter pylori treatment failures: the super salvage regimen. Helicobacter. 2003;8(4):307–309. - PubMed
LinkOut - more resources
Full Text Sources
